Feed PRVA
PR

Privia PRVA · NASDAQ

$22.47 -2.01% (-$0.46)

Summary

48 / 100 · Bulios Score

What speaks for it

  • Revenue grew by 16% a year over the last 3 years.
  • It holds more cash than debt: $412.2B against $8.73B.
  • The share price is below the Bulios Fair Price.
  • Analysts expect revenue to grow by 16% this fiscal year.

What to watch

  • Out of every 100 USD of revenue, only 1.2 USD is left as net profit.
  • It missed profit estimates 6 times in the last 8 quarters.
  • It passes only 2 of the 9 points of the Piotroski financial health test.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Current price $22.47
P/E today 101.9 29% lower
5-year average P/E 142.8
P/E today 101.9
Medical - Healthcare Information Services industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 101.9 USD for 1 USD of yearly profit. Over the last five years it was 142.8 USD on average.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 21% a year over 5 years. Over the last 3 years it grew by 16% a year. For the next fiscal year analysts expect revenue to grow by 16%.

Growth in detail

Does it make money?

Poorly

Where 100 USD of revenue goes

Net profit, industry median (Medical - Healthcare Information Services) 4.7 USD

Out of every 100 USD of revenue, 1.2 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $27.33 is 22% above today's price. 91% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

The company reports no revenue by region.

FFS-Patient Care brings in 64% of revenue. Shared Savings grew fastest, by 30% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.